For Immediate Release
October 6, 2025
QXMédical Announces Settlement with Teleflex, Clearing Path for U.S. Launch of Boosting Catheter in 2026
Saint Paul, MN — QXMédical, LLC today announced that it has reached a definitive settlement with Teleflex Incorporated to resolve the companies’ patent dispute concerning QXMédical’s Boosting Catheter guide extension catheter.
Under the terms of the settlement, the federal lawsuit between the companies has been dismissed, bringing closure to the litigation. This resolution clears the way for QXMédical to introduce the Boosting Catheter to the United States market in 2026, expanding treatment options for physicians performing complex coronary interventions.
“We are pleased to bring this matter to a close and move forward with our mission of supporting interventional cardiologists and their patients with innovative tools designed to simplify the most challenging cases,” said Fernando Di Caprio, President and Chief Technology Officer of QXMédical. “The Boosting Catheter has already demonstrated significant interest abroad, with a strong clinical history of more than 50,000 uses worldwide. We are excited to bring its unique performance advantages to physicians and patients in the United States.”
The Boosting Catheter is designed to provide additional back-up support and facilitate device delivery in complex percutaneous coronary interventions (PCI), including chronic total occlusions (CTO) and heavily calcified lesions. Its patented construction enables unmatched trackability, large device passage capability, and exceptional support, giving physicians greater control in the most demanding procedures. The Boosting Catheter is manufactured in our state-of-the-art facility in Saint Paul, Minnesota, reflecting QXMédical’s ongoing commitment to U.S.-based production and quality.
About QXMédical
QXMédical, LLC is a privately held medical device company headquartered in Minnesota, USA, dedicated to developing and commercializing innovative interventional cardiology and peripheral vascular technologies. With a portfolio that includes the Boosting Catheter guide extension, the i-Flex™ rapidly resorbable embolization particles, and other novel catheter-based solutions, QXMédical partners with leading physicians and distributors worldwide to deliver products that improve procedural outcomes, simplify techniques, and expand access to advanced care. The company maintains a strong focus on U.S.-based manufacturing to ensure quality, reliability, and responsive supply for its customers.
